Henlius has built an integrated and efficient global R&D platform with key facilities in Shanghai and California closely collaborating with each other to ensure the highly productive and cost-efficient R&D processes. California R&D Centre is responsible for early-stage R&D with a focus on cell line construction and screening. It has established a bispecific antibody engineering platform including synthetic humanised llama VHH library (2x1012), VHH- and scFv-based bispecific screening and engineering and linker design. Shanghai R&D centre is responsible for R&D in later stages including upstream/downstream process development, formulation development and analytical process development with continuous exploration in cutting-edge production technologies.
